PL1756310T3 - Sposób wykrywania polimorfizmów w genie ABCB1 związanych z brakiem odpowiedzi na lek działający na OUN oraz lek zawierający inhibitor ABCB1 do stosowania w leczeniu chorób związanych z OUN - Google Patents

Sposób wykrywania polimorfizmów w genie ABCB1 związanych z brakiem odpowiedzi na lek działający na OUN oraz lek zawierający inhibitor ABCB1 do stosowania w leczeniu chorób związanych z OUN

Info

Publication number
PL1756310T3
PL1756310T3 PL05748517T PL05748517T PL1756310T3 PL 1756310 T3 PL1756310 T3 PL 1756310T3 PL 05748517 T PL05748517 T PL 05748517T PL 05748517 T PL05748517 T PL 05748517T PL 1756310 T3 PL1756310 T3 PL 1756310T3
Authority
PL
Poland
Prior art keywords
cns
medicament
abcb1
lack
response
Prior art date
Application number
PL05748517T
Other languages
English (en)
Inventor
Manfred Uhr
Florian Holsboer
Elisabeth Binder
Bertram Müller-Myhsok
Original Assignee
Max Planck Gesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft filed Critical Max Planck Gesellschaft
Publication of PL1756310T3 publication Critical patent/PL1756310T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/172Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL05748517T 2004-05-12 2005-05-12 Sposób wykrywania polimorfizmów w genie ABCB1 związanych z brakiem odpowiedzi na lek działający na OUN oraz lek zawierający inhibitor ABCB1 do stosowania w leczeniu chorób związanych z OUN PL1756310T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57008504P 2004-05-12 2004-05-12
PCT/EP2005/005194 WO2005108605A2 (en) 2004-05-12 2005-05-12 Polymorphisms in abcb1 associated with a lack of clinical response to medicaments
EP05748517A EP1756310B1 (en) 2004-05-12 2005-05-12 Method for detecting polymorphisms in the ABCB1 gene associated with a lack of response to a CNS-active medicament and medicament comprising an ABCB1 inhibitor for use in the treatment of CNS related diseases.

Publications (1)

Publication Number Publication Date
PL1756310T3 true PL1756310T3 (pl) 2013-05-31

Family

ID=34979627

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05748517T PL1756310T3 (pl) 2004-05-12 2005-05-12 Sposób wykrywania polimorfizmów w genie ABCB1 związanych z brakiem odpowiedzi na lek działający na OUN oraz lek zawierający inhibitor ABCB1 do stosowania w leczeniu chorób związanych z OUN

Country Status (6)

Country Link
US (1) US8030033B2 (pl)
EP (1) EP1756310B1 (pl)
DK (1) DK1756310T3 (pl)
ES (1) ES2397345T3 (pl)
PL (1) PL1756310T3 (pl)
WO (1) WO2005108605A2 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2356789T3 (es) 2006-07-14 2011-04-13 The Govt. Of The Usa As Represented By The Secretary Of The Dept. Of Health And Human Services Genotipado abcb1 para predecir toxicidad inducida por un agente estabilizador de microtúbulos.
ES2394529T3 (es) 2007-06-12 2013-02-01 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Nuevos polimorfismos en ABCB1 asociados con una falta de respuesta clínica a medicamentos
EP2670866A4 (en) * 2011-04-05 2015-09-02 Translational Genomics Res Inst BIOMARKERS AND METHODS OF USE
CN108929913A (zh) * 2018-08-21 2018-12-04 潍坊德诺泰克生物科技有限公司 用于检测rs2032582的引物探针组及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE373710T1 (de) 1999-07-30 2007-10-15 Epidauros Ag Biotechnologie Ag Polymorphismus im humanen mdr-1 gen und dessen verwendung
US7034036B2 (en) 2000-10-30 2006-04-25 Pain Therapeutics, Inc. Inhibitors of ABC drug transporters at the blood-brain barrier
US20050069936A1 (en) * 2003-09-26 2005-03-31 Cornelius Diamond Diagnostic markers of depression treatment and methods of use thereof

Also Published As

Publication number Publication date
US20080064609A1 (en) 2008-03-13
DK1756310T3 (da) 2013-03-18
WO2005108605A2 (en) 2005-11-17
EP1756310B1 (en) 2012-12-05
ES2397345T3 (es) 2013-03-06
WO2005108605A3 (en) 2006-01-12
US8030033B2 (en) 2011-10-04
EP1756310A2 (en) 2007-02-28

Similar Documents

Publication Publication Date Title
ZA200703714B (en) 5-heteroaryl thiazoles and their use as P13K inhibitors
EP1651251A4 (en) METHOD FOR THE TREATMENT OF DIABETES AND RELATED DISEASES USING PDE 10A INHIBITORS
EP1774029A4 (en) METHOD FOR DETECTING THE RISKS OF NON-INSULIN-DEPENDENT DIABETES AND FOR TREATING THIS TYPE OF DIABETES
TWI368272B (en) Cleaning liquid and cleaning method
EP1752536A4 (en) POLYNUCLEOTIDE CAUSING RNA INTERFERENCE AND METHOD OF REGULATING GENE EXPRESSION WITH THE USE OF THE SAME
ZA200704668B (en) An austenitic steel and steel product
IL180759A0 (en) Indazoles useful in treating cardiovascular diseases
IL180872A0 (en) Substituted 8-aminoalkylthio-xanthines, and the use thereof as inhibitors of the dipeptidyl peptidase iv
EP1933880A4 (en) OLIGORIBONUCLEOTIDES AND METHODS OF USE IN THE TREATMENT OF CARDIOVASCULAR DISEASES
GB0704021D0 (en) Computer hypnosis therapy device and method
GB2416542B (en) Fuel product and process
GB0625320D0 (en) Direct type backlight unit and method for forming diffuser in the direct type backlight unit
EP2069541A4 (en) POLYMORPHISMS IN GENES AFFECTING DISORDERS OF THE CENTRAL NERVOUS SYSTEM AND USES THEREOF
IL185554A0 (en) Method of prognosis of mental diseases, e.g. sutism and cerebral palsy
GB0504890D0 (en) Process management system and produciton management system
PL2026821T3 (pl) Binarne mieszaniny kwasu hialuronowego i ich zastosowanie terapeutyczne
EP2134863A4 (en) GENETIC MODIFICATIONS ON CHROMOSOME 16 AND METHODS OF USING THE SAME FOR THE DIAGNOSIS AND TREATMENT OF TYPE I DIABETES
PL1740298T3 (pl) Sposób granulacji złoża zawiesinowego
PL1756310T3 (pl) Sposób wykrywania polimorfizmów w genie ABCB1 związanych z brakiem odpowiedzi na lek działający na OUN oraz lek zawierający inhibitor ABCB1 do stosowania w leczeniu chorób związanych z OUN
EP1963521A4 (en) THERAPEUTIC USE FOR THE INHIBITOR OF ALPHA 1 PROTEINASE IN HEMATOPOIESE
EP2097378A4 (en) NOVEL INHIBITORS OF SEH AND USE THEREOF
WO2005076892A3 (en) Method for determining reduced susceptibility of hiv to protease inhibitor treatment
EP2019590A4 (en) METHODS FOR TREATING DISEASES INVOLVING STRESS-RELATED CONDITIONS AND CONDITIONS
AU2003241400A8 (en) Amyotrophic lateral sclerosis treatment with cyclooxygenase-2 inhibitors
GB0402629D0 (en) Reactor and process